A comparison of the relative efficacy of antiandrogens for the treatment of acne in hyperandrogenic women
- PMID: 12153602
- DOI: 10.1046/j.1365-2265.2002.01594.x
A comparison of the relative efficacy of antiandrogens for the treatment of acne in hyperandrogenic women
Abstract
Objectives: To compare the relative effectiveness of two newer antiandrogens (flutamide and finasteride) with cyproterone acetate (CPA), at both low and high doses in the treatment of moderate to severe acne in hyperandrogenic women.
Subjects and design: Forty-eight hyperandrogenic women were prospectively randomized to the following treatments for 1 year: CPA 2 mg with 35 micro g ethinylestradiol; CPA 50 mg with 25 micro g ethinylestradiol (reverse sequential regimen); flutamide 250 mg daily; and finasteride 5 mg daily. Assessment of Cook scores was the primary end-point of the trial. Blood for androgens was obtained at baseline in these women and 30 ovulatory age-matched controls.
Results: Serum androgens were elevated in all 48 women and was similar in each of the four treatment groups. Cook scores were significantly and equally decreased (59-71%) with flutamide and both low and high doses of CPA (P < 0.01). The decrease with finasteride (-36 +/- 2%) was statistically significant but lower than that obtained with the other agents. All treatments were well tolerated.
Conclusions: In hyperandrogenic women with moderate to severe acne, low doses of certain antiandrogens appear to be effective. Low and high doses of CPA with ethinylestradiol were equally effective and were comparable to the effects of a low dose of flutamide. Finasteride was less beneficial.
Comment in
-
Different effectiveness of cyproterone acetate doses in treatment of acne.Clin Endocrinol (Oxf). 2003 Feb;58(2):246. doi: 10.1046/j.1365-2265.2003.16911.x. Clin Endocrinol (Oxf). 2003. PMID: 12580942 No abstract available.
Similar articles
-
Treatment of hirsutism: comparisons between different antiandrogens with central and peripheral effects.Fertil Steril. 1999 Mar;71(3):445-51. doi: 10.1016/s0015-0282(98)00486-5. Fertil Steril. 1999. PMID: 10065780 Clinical Trial.
-
Treatment of hyperandrogenic alopecia in women.Fertil Steril. 2003 Jan;79(1):91-5. doi: 10.1016/s0015-0282(02)04551-x. Fertil Steril. 2003. PMID: 12524069 Clinical Trial.
-
The use of cyproterone acetate/ethinyl estradiol in hyperandrogenic skin symptoms - a review.Eur J Contracept Reprod Health Care. 2017 Jun;22(3):172-182. doi: 10.1080/13625187.2017.1317339. Epub 2017 Apr 27. Eur J Contracept Reprod Health Care. 2017. PMID: 28447864 Review.
-
Prescribing of cyproterone acetate/ethinylestradiol in UK general practice: a retrospective descriptive study using The Health Improvement Network.Contraception. 2017 Mar;95(3):299-305. doi: 10.1016/j.contraception.2016.10.003. Epub 2016 Oct 18. Contraception. 2017. PMID: 27769766
-
Anti-androgen treatments.Ann Endocrinol (Paris). 2010 Feb;71(1):19-24. doi: 10.1016/j.ando.2009.12.001. Epub 2010 Jan 22. Ann Endocrinol (Paris). 2010. PMID: 20096826 Review.
Cited by
-
Oral Spironolactone for Acne Vulgaris in Adult Females: A Hybrid Systematic Review.Am J Clin Dermatol. 2017 Apr;18(2):169-191. doi: 10.1007/s40257-016-0245-x. Am J Clin Dermatol. 2017. PMID: 28155090 Free PMC article.
-
Therapeutic androgen receptor ligands.Nucl Recept Signal. 2003;1:e009. doi: 10.1621/nrs.01009. Epub 2003 Sep 27. Nucl Recept Signal. 2003. PMID: 16604181 Free PMC article.
-
Androgen Receptor Inhibitors in the Treatment of Acne Vulgaris: Efficacy and Safety Profiles of Clascoterone 1% Cream.Clin Cosmet Investig Dermatol. 2022 Jul 15;15:1357-1366. doi: 10.2147/CCID.S289750. eCollection 2022. Clin Cosmet Investig Dermatol. 2022. PMID: 35874458 Free PMC article. Review.
-
Efficacy and safety of combined ethinyl estradiol/drospirenone oral contraceptives in the treatment of acne.Int J Womens Health. 2010 Aug 9;1:213-21. doi: 10.2147/ijwh.s3916. Int J Womens Health. 2010. PMID: 21072290 Free PMC article.
-
Female Adult Acne and Androgen Excess: A Report From the Multidisciplinary Androgen Excess and PCOS Committee.J Endocr Soc. 2022 Feb 6;6(3):bvac003. doi: 10.1210/jendso/bvac003. eCollection 2022 Mar 1. J Endocr Soc. 2022. PMID: 35155970 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical